NBC Exec on Why the Ad Community Has to Change Its Strategy
NBC is hitting the ground running in 2018. The company is broadcasting the Golden Globes, the Super Bowl, and the Pyeongchang’s 2018 Winter Olympics. And to shake things up, the media giant is focusing on marrying digital and linear content strategies. The action plan’s goal is to give viewers whatever they need, whether they’re at home, work, or on the go.
Linda Yaccarino, NBC Universal’s Chairwoman of Advertising Sales & Client Partnerships, says that next year, advertisers are concerned with content and dominance on all platforms.
“It’s more of a multi-screen opportunity, [as opposed to] one versus the other,” she said.
The executive told Cheddar that the hardest part of marketing to the modern consumer is not falling back on legacies of process and commitment. Consumers have drastically changed the way they absorb content and make purchasing decisions. Yaccarino, who manages $10 billion in ad sales, says marketers need to change up their strategies.
“Buying, planning, and executing media happens today pretty much the same way it’s always happened,” she says. “We have to really challenge the industry processes to reflect consumer behavior.”
For full interview [click here.] ( https://cheddar.com/videos/nbcuniversals-linda-yaccarino-expect-1-billion-in-revenue-for-2018-olympics)
The health and wellness industry is booming, expected to hit $14 trillion by 2032. Equinox teamed up with Function Health to revolutionize health optimization.
Featherie, a line of sustainable and functional golf wear for girls, fills a void in the market, catering to the increasing number of female junior golfers.
The CEO of LiveOne, Rob Ellin, discusses the DOJ's lawsuit against Live Nation and Ticketmaster, how will if affect you and the future of live events. Watch!
Nvidia did a record $26 billion in sales in the latest quarter. And get ready for the stock to keep climbing, because the A.I. boom is just getting started.
In honor of National Cancer Research Month, Perspective Therapeutics discusses its latest treatment — currently in clinical trials — that targets cancer cells d